FDANews

LAB INTERNATIONAL BEGINS ENROLLMENT IN FENTANYL TAIFUN TRIAL

LAB International has announced the enrollment of the first patients in its Fentanyl TAIFUN Phase IIb clinical trial. Fentanyl TAIFUN is a fast-acting Fentanyl formulation delivered using the company's TAIFUN dry powder inhaler platform.

The multicenter, multinational, dose-titration, single-arm and open-label trial is evaluating the time to significant pain relief with Fentanyl TAIFUN with successful titration in the treatment of breakthrough cancer pain. The trial is enrolling 32 cancer patients on maintenance opioid therapy for persistent pain.